Your fact-checks will appear here
Medicare covers FDA-approved monoclonal antibody Alzheimer's drugs under Part B with certain conditions
enacted and began implementing laws and policies that lower prescription drug costs for many Americans, particularly people with , chiefly through ’s negotiation authority, an inflation rebate program...
Patients prescribed 2025 FDA‑approved Alzheimer’s drugs face variable but often substantial out‑of‑pocket exposure that depends on the drug’s list price, Medicare cost‑sharing rules, required diagnost...